Enzymatic and Biological Characterization of Novel Sirtuin Modulators against Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

1. Benzodeazaoxaflavin Sirtuin Inhibitors InhibitACS infectious diseases · 2025
   Article
2. Activation and inhibition of sirtuins: From bench to bedside.Medicinal research reviews · 2025
   Review
3. The dual role of sirtuins in cancer: biological functions and implications.Frontiers in oncology · 2024
   Review
4. Sirtuin modulators: past, present, and future perspectives.Future medicinal chemistry · 2022
   Review
5. ArylamineFrontiers in pharmacology · 2022
   Article
6. The Pan-Sirtuin Inhibitor MC2494 Regulates Mitochondrial Function in a Leukemia Cell Line.Frontiers in oncology · 2020
   Article
7. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.Frontiers in cell and developmental biology · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

14 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as